Influenza virus vaccine, live, intranasal

Influenza Virus Vaccine, Live, Intranasal (FluMist)... 

Influenza virus vaccine live intranasal-medimmune vaccines CATV-T, influenza vaccine live intranasal. Dmgs R D 2003, 4 (5), 312-319. 

FluMist (Influenza virus vaccine live, intranasal). Medimmune Vaccines, Inc. US Prescribii information, January 2007. 

Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998 338 1405-1412. 

Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults A randomized, controlled trial. JAMA 1999 282 137-144. 

In a randomized, double-blind study, trivalent, live, attenuated, cold-adapted intranasal influenza vaccine (FluMist) has been compared with intranasal placebo plus a trivalent injected inactivated influenza vaccine (5). The 200 patients were aged 65 years and over and had chronic cardiovascular or pulmonary conditions or diabetes mellitus. During the 7 days after immunization, sore throat was reported on at least one day by significantly more of the FluMist recipients (15 versus 2%). The increased frequency of sore throat may have been attributable to direct or indirect effects of vaccine virus replication. No other symptom was associated with FluMist. These findings were consistent with evaluations of other live, attenuated, cold-adapted influenza vaccine formulations in older adults. However, further studies of the safety of FluMist are warranted. 

---